Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm

JAMA Psychiatry
Donovan T MaustHelen C Kales

Abstract

Antipsychotic medications are associated with increased mortality in older adults with dementia, yet their absolute effect on risk relative to no treatment or an alternative psychotropic is unclear. To determine the absolute mortality risk increase and number needed to harm (NNH) (ie, number of patients who receive treatment that would be associated with 1 death) of antipsychotic, valproic acid and its derivatives, and antidepressant use in patients with dementia relative to either no treatment or antidepressant treatment. A retrospective case-control study was conducted in the Veterans Health Administration from October 1, 1998, through September 30, 2009. Participants included 90,786 patients 65 years or older with a diagnosis of dementia. Final analyses were conducted in August 2014. A new prescription for an antipsychotic (haloperidol, olanzapine, quetiapine, and risperidone), valproic acid and its derivatives, or an antidepressant (46,008 medication users). Absolute change in mortality risk and NNH over 180 days of follow-up in medication users compared with nonmedication users matched on several risk factors. Among patients in whom a treatment with medication was initiated, mortality risk associated with each agent was al...Continue Reading

Citations

Feb 19, 2016·International Journal of Geriatric Psychiatry·Donovan T MaustHelen C Kales
Feb 24, 2016·Ageing Research Reviews·Bart De SpiegeleerSofie Stalmans
Jan 20, 2016·Current Psychiatry Reports·James M Wilkins, Brent P Forester
Nov 26, 2015·Pharmacoepidemiology and Drug Safety·Hendrika J LuijendijkXander Koolman
Dec 24, 2015·Current Psychiatry Reports·Aaron M KoenigJoel E Streim
Oct 20, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Jens BohlkenJörg Bätzing-Feigenbaum
Mar 6, 2016·European Journal of Clinical Pharmacology·Xavier VidalUNKNOWN Potentially Inappropriate Prescription in Older Patients in Spain (PIPOPS) Investigators’ project
Dec 27, 2015·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Helen C Kales
Dec 3, 2015·Der Nervenarzt·R HaussmannM Donix
Feb 18, 2016·Expert Review of Neurotherapeutics·Radoslaw Magierski, Tomasz Sobow
Oct 9, 2015·Journal of the American Geriatrics Society·UNKNOWN By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel
May 25, 2016·The Psychiatric Clinics of North America·Donna AmesLynn M Yudofsky
Jul 28, 2015·Biochemical Pharmacology·Alan S LewisMarina R Picciotto
Apr 12, 2016·Journal of Hospital Medicine : an Official Publication of the Society of Hospital Medicine·Kah Poh LohTara Lagu
Jul 3, 2015·Current Treatment Options in Neurology·Jennifer Rose V MolanoRhonna Shatz
Feb 26, 2016·Expert Review of Neurotherapeutics·Stefan Hermanowicz, Neal Hermanowicz
Jun 17, 2016·Journal of Palliative Medicine·Meera R AgarDavid C Currow
Jul 20, 2016·Journal of the American Geriatrics Society·Teresa FilshteinGlen L Xiong
Aug 1, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Niklas SchmedtTania Schink
Jul 28, 2016·Expert Opinion on Pharmacotherapy·William James Deardorff, George T Grossberg
Sep 16, 2016·Frontiers in Endocrinology·Adonis SferaMichael Cummings
Oct 4, 2016·Journal of Critical Care·David J GagnonGilles L Fraser
Oct 5, 2016·International Journal of Geriatric Psychiatry·Ryan M SilwanowiczHelen C Kales
Nov 12, 2016·The Psychiatric Clinics of North America·Jonathan M MeyerStephen M Stahl
Dec 21, 2016·Journal of the American Geriatrics Society·Dongjuan XuTeresa M Lewis
Feb 12, 2017·European Journal of Anaesthesiology·César AldecoaClaudia D Spies
Jan 24, 2017·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Martin R Farlow, Tatyana A Shamliyan
Mar 24, 2017·Brain : a Journal of Neurology·Suzanne ReevesRobert Howard
Apr 1, 2017·Clinical Drug Investigation·Stephane CheungSunny Tsukazawa
May 27, 2017·BMC Pharmacology & Toxicology·Jon BrännströmYngve Gustafson
Jan 13, 2017·Current Opinion in Psychiatry·Orestes V ForlenzaFlorindo Stella
Sep 2, 2016·Therapeutic Advances in Chronic Disease·Rajesh R TampiShilpa Srinivasan
Aug 10, 2016·Journal of Geriatric Psychiatry and Neurology·Tor Atle RosnessZeina Chemali
Jul 26, 2017·International Journal of Geriatric Psychiatry·Emma McLachlanSuzanne Reeves

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry
Connie MarrasPaula Rochon
Progress in Neuro-psychopharmacology & Biological Psychiatry
Michael T LambertSonia A Duffy
Journal of the American Geriatrics Society
Sally K RiglerJonathan D Mahnken
© 2021 Meta ULC. All rights reserved